Bain Capital Life Sciences Investors, LLC Q4 2023 Portfolio
Sym
Weight
Trade Impact
Company
Class
Share Change
Activity
Value Change $
Value $
* Price $
Shares
Principal
Filing 2023 Q4 compared to 2023 Q3 by default. Changes are calculated vs the previous SEC filing.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
Person Signing this Report on Behalf of Reporting Manager:
Name
Title
City, State
Date
Adam Koppel
Partner of Bain Capital Life Sciences Investors, LLC
Boston, Massachusetts
13 Feb 2024
Bain Capital Life Sciences Investors, LLC ("BCLSI") is (i) the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of Bain Capital Life Sciences Fund, L.P., (ii) the general partner of BC SW, LP, (iii) the manager of Bain Capital Life Sciences Investors II, LLC, which is the general partner of Bain Capital Life Sciences Fund II, L.P., which is the manager of BCLS II Investco (GP), LLC, which is the general partner of BCLS II Investco, LP, and (iv) the manager of Bain Capital Life Sciences III General Partner, LLC, which is the general partner of Bain Capital Life Sciences Fund III, L.P., which is the sole member of Bain Capital Life Sciences Opportunities III GP, LLC, which is the general partner of Bain Capital Life Sciences Opportunities III, LP. The shares of Annexon, Inc. ("ANNX") are as reported on Amend. No. 3 to Schedule 13G filed by affiliates of BCLSI on 2/13/24 and reflect the exercise of securities held by such persons for ANNX common stock, after giving effect to 9.99% conversion blockers. As of 12/31/23, such persons held 5,701,926 shares of ANNX common stock. The shares of Savara Inc. ("SVRA") are as reported on Amend. No. 2 to Schedule 13D filed by affiliates of BCLSI on 7/19/23 and reflect the exercise of securities held by such persons for SVRA common stock, after giving effect to 9.99% conversion blockers. As of 12/31/23, such persons held 6,913,208 shares of SVRA common stock. The shares of Syros Pharmaceuticals, Inc. ("SYRS") are as reported on Amend. No. 3 to Schedule 13G filed by affiliates of BCLSI on 2/13/24 and reflect the exercise of securities held by such persons for SYRS common stock, after giving effect to 9.99% conversion blockers. As of 12/31/23, such persons held 1,230,857 shares of SYRS common stock. The shares of X4 Pharmaceuticals, Inc. ("XFOR") are as reported on Amend. No. 3 to Schedule 13G filed by affiliates of BCLSI on 2/13/24 and reflect the exercise of securities held by such persons for XFOR common stock, after giving effect to 9.99% conversion blockers. As of 12/31/23, such persons held 14,879,809 shares of XFOR common stock.
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.